$RETA Jefferies raises PT to $333 ahead of Q4 update. Anticipates incremental updates related to bard and omav regulatory filings, potential APDKD status update and some tidbits on upcoming phase 3 CTD-PAH readout
$ARNA –particularly undervalued (particularly considering cash equivalents are ~$1.2B) stock as most attractive to holders with a time horizon that extends through at least YE21. In our view, S1Ps will be an attractive drug class for ulcerative colitis and other diseases
JPMorgan raises PT for $CCXI to $60, keeps an Overweight rating
$XAIR has about 20% insider ownership & most of shares bought on the market over past year with broad insider purchases in June PIPE & December. There were very few windows to buy & whenever there is they buy aggressively.
$BLPH H.C. Wainwright Buy Rating PT $30
CS $ESPR approval widely expected